Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
NCT07201129

A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

Led by Viatris Innovation GmbH · Updated on 2026-04-28

300

Participants Needed

9

Research Sites

207 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to learn if cenerimod, on top of regular treatment, works to treat active lupus nephritis in adults with systemic lupus erythematosus and active lupus nephritis. It will also learn about the safety of cenerimod. The main questions it aims to answer are: * Does cenerimod improve kidney function in participants? * What medical problems do participants have when taking cenerimod? Researchers will compare cenerimod to a placebo (a look-alike substance that contains no drug) to see how well cenerimod works when it is added to regular treatment. Participants will: * Take cenerimod or a placebo every day for 76 weeks (approximately 1.5 years), on top of regular treatment. * Visit the clinic every 1 to 3 months for checkups and tests.

CONDITIONS

Official Title

A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 to 75 years
  • Diagnosed with systemic lupus erythematosus according to 2019 EULAR/ACR criteria
  • Kidney biopsy within 6 months showing Class III, IV, or pure Class V lupus nephritis, or biopsy performed during screening
  • Active renal disease with urine protein/creatinine ratio ≥ 1 mg/mg
  • Estimated glomerular filtration rate (eGFR) ≥ 15 mL/min/1.73 m²
  • For eGFR between 15 and <30, biopsy must show ≤ 50% glomeruli sclerosis, activity index ≥ 2, and chronicity index < 4
  • Starting or already on induction therapy including mycophenolate mofetil 1-3 g/day (or mycophenolate sodium 720-2160 mg/day)
  • Corticosteroids given as 1-3 intravenous pulses followed by oral prednisone 0.5 mg/kg/day (max 40 mg/day), or direct oral prednisone 0.8-1.0 mg/kg/day (max 80 mg/day)
  • If on antimalarial or belimumab, treatment must be stable for at least 4 weeks before screening and continue stable during study
  • Participants of childbearing potential must agree to highly effective contraception and monthly pregnancy tests during and 24 weeks after treatment
Not Eligible

You will not qualify if you...

  • Severe active central nervous system lupus
  • Other kidney diseases affecting lupus nephritis assessment or requiring dialysis or transplant
  • History or current serious heart rhythm problems including Mobitz II or third-degree AV block, sick sinus syndrome, symptomatic bradycardia, or syncope
  • Recent (within 6 months) serious heart events like heart attack, unstable angina, stroke, or heart failure requiring hospitalization
  • Resting heart rate below 50 bpm at screening or randomization
  • Active or latent tuberculosis at screening or within 6 months prior
  • Negative varicella-zoster virus antibody test
  • Positive hepatitis A, B, C, or E infection markers
  • Positive HIV test or other immunodeficiency
  • Eye problems such as macular edema, foveal degeneration, active uveitis, papilledema, or retinal neovascularization
  • Significant blood abnormalities including very low hemoglobin, lymphocytes, white blood cells, or platelets
  • Recent use of certain immunosuppressive or biologic treatments within specified timeframes
  • Previous participation in cenerimod trials
  • Pregnancy or breastfeeding

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 9 locations

1

Alloy Clinical Research LLC

Kissimmee, Florida, United States, 34741

Actively Recruiting

2

SouthCoast Research Center

Miami, Florida, United States, 33136

Actively Recruiting

3

Allied Biomedical Research Institute

Miami, Florida, United States, 33155

Actively Recruiting

4

DH NationalResearchCenters INC

Miami, Florida, United States, 33155

Actively Recruiting

5

ProfessionalResearchCenter INC

Miami, Florida, United States, 33172

Actively Recruiting

6

San Marcus Research Clinic, Inc.

Miami Lakes, Florida, United States, 33014

Actively Recruiting

7

Rheumatology Care Center, PLLC

Bellaire, Texas, United States, 77401

Actively Recruiting

8

Novel Research, LLC.

Houston, Texas, United States, 77024

Actively Recruiting

9

Northwest Houston Arthritis

Houston, Texas, United States, 77090

Actively Recruiting

Loading map...

Research Team

V

Viatris Innovation Clinical Trial Information

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment | DecenTrialz